What You Need to Know About AstraZeneca PLC's Q3 Earnings
AstraZeneca PLC's fiscal Q3 earnings report was released on Monday, July 27. Let's dive in to see if (AZN) missed or beat analyst's expectations.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Commentary & Analysis
Is AstraZeneca PLC (AZN) Overvalued?
We dive into why AstraZeneca PLC (AZN) could be considered overvalued on 2026-07-14, based on AAII’s Value Score and Grade.Jenna Brashear
Is AstraZeneca PLC (AZN) Overvalued?
We dive into why AstraZeneca PLC (AZN) could be considered overvalued on 2026-07-13, based on AAII’s Value Score and Grade.Michael Rose
Is AstraZeneca PLC (AZN) Overvalued?
We dive into why AstraZeneca PLC (AZN) could be considered overvalued on 2026-07-10, based on AAII’s Value Score and Grade.Jenna Brashear
Is AstraZeneca PLC (AZN) Overvalued?
We dive into why AstraZeneca PLC (AZN) could be considered overvalued on 2026-07-09, based on AAII’s Value Score and Grade.Tudor Pop
Financial Summary
| Share Statistics | AZN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $263,267.9 | $569.9 | 99% |
|
| Shares Out (Mil) | 1,560.0 | 44.8 | 96% |
|
| Institutional Ownership | 99.9% | 84.6% | 96% |
|
| Float (Mil) | 1,543.2 | 45.1 | 94% |
|
| Beta | 0.22 | 0.67 | 13% |
|
| Avg Daily Volume (000s) | 2,572 | 294 | 86% |
|
| Price Change (52-week) |
20.1% | 65.2% | 62% |
|
| Growth | AZN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 17.2% | 6.7% | 77% |
|
| Net Income (5yr) | 26.2% | (2.0%) | 81% |
|
| EPS (5yr) | 21.8% | 14.9% | 71 |
|
| Dividends (5yr) | 2.7% | 0.0% | 95% |
|
| Cash Flow (5yr) | (37.4%) | (14.9%) | 13% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 4 | 4 | |
| Current EPS | $1.279 | $7.600 | $8.684 | |
| Month Ago EPS | $2.691 | $10.387 | $11.646 | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 1 | 1 | 2 | |
| Three Months Ago EPS | $2.688 | $10.387 | $11.625 | |
| Year/Year Chg | (20.6%) | 16.2% | 97.9% | |
| Financials | AZN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $61,366 | $230 | 97% |
|
| Net Income (TTM) (Mil) | $10,446 | ($11) | 99% |
|
| EPS (TTM) | $6.739 | ($0.600) | 91% |
|
| Operating Cash Flow (TTM) (Mil) | $13,700 | ($6) | 99% |
|
| Net Cash Flow (TTM) (Mil) | ($2,148) | $4 | 2% |
|
| Long-Term Debt (Q1) (Mil) | $26,008 | $7 | 96% |
|
| Enterprise Value (Q1) (Mil) | $298,087 | $493 | 99% |
|
| Valuation | AZN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.28 | 2.89 | 79% |
|
| P/E | 25.6 | 20.6 | 62% |
|
| Dividend Yield | 1.4% | 0.0% | 71% |
|
| PEG (5yr hist) | 1.2 | 1.1 | 50% |
|
| Ratios | AZN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 81.7% | 65.9% | 90% |
|
| Net Margin | 17.0% | (0.2%) | 76% |
|
| ROA | 9.2% | (25.5%) | 86% |
|
| ROE | 22.0% | (21.4%) | 82% |
|
| Liabilities to Assets | 56.5% | 35.5% | 49% |
|
| F-Score | 7 | 3 | 84% |
|
AstraZeneca PLC did not pass any screens on 7/30/2026.
